Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Mallinckrodt
Dow
AstraZeneca
Colorcon

Last Updated: May 26, 2022

CLINICAL TRIALS PROFILE FOR LAMPRENE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Lamprene

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01290744 ↗ Effect of Additional Clofazimine on Erythema Nodosum Leprosum (ENL) Reactions in Leprosy Completed Paul Saunderson Phase 4 2010-08-01 This study is a double-blind, randomized controlled trial examining the effect on ENL reactions of giving an additional year of clofazimine after completion of MDT in leprosy.
NCT02409290 ↗ The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB Active, not recruiting Institute of Tropical Medicine, Belgium Phase 3 2016-04-01 Tuberculosis (TB) is a common, infectious, bacterial disease that is spread when an infected person transmits their saliva through the air by coughing or sneezing. Despite the availability and effectiveness of affordable six-month treatments for tuberculosis (TB), the worldwide control of this disease is currently being impacted by the emergence of multidrug resistant TB (MDR-TB). MDR-TB refers to TB that is resistant to at least isoniazid and rifampicin. These are the two most powerful first-line drugs used to treat pulmonary TB. MDR-TB usually develops while a person is taking TB treatment due to either inappropriate treatment or failure of patients to comply with their treatment. This strain of drug-resistant bacteria can also be spread to other people through the air. With the incident rate of MDR-TB on the rise, there is a need to investigate optimal treatment regimens using effective drugs.
NCT02409290 ↗ The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB Active, not recruiting Liverpool School of Tropical Medicine Phase 3 2016-04-01 Tuberculosis (TB) is a common, infectious, bacterial disease that is spread when an infected person transmits their saliva through the air by coughing or sneezing. Despite the availability and effectiveness of affordable six-month treatments for tuberculosis (TB), the worldwide control of this disease is currently being impacted by the emergence of multidrug resistant TB (MDR-TB). MDR-TB refers to TB that is resistant to at least isoniazid and rifampicin. These are the two most powerful first-line drugs used to treat pulmonary TB. MDR-TB usually develops while a person is taking TB treatment due to either inappropriate treatment or failure of patients to comply with their treatment. This strain of drug-resistant bacteria can also be spread to other people through the air. With the incident rate of MDR-TB on the rise, there is a need to investigate optimal treatment regimens using effective drugs.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Lamprene

Condition Name

Condition Name for Lamprene
Intervention Trials
Extensively Drug-Resistant Tuberculosis 4
Tuberculosis, Multidrug-Resistant 3
Pulmonary Tuberculoses 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Lamprene
Intervention Trials
Tuberculosis, Multidrug-Resistant 8
Tuberculosis 8
Tuberculosis, Pulmonary 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Lamprene

Trials by Country

Trials by Country for Lamprene
Location Trials
South Africa 15
United States 6
Uzbekistan 6
Belarus 4
Philippines 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Lamprene
Location Trials
Texas 1
Oregon 1
Maryland 1
Illinois 1
District of Columbia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Lamprene

Clinical Trial Phase

Clinical Trial Phase for Lamprene
Clinical Trial Phase Trials
Phase 4 1
Phase 3 3
Phase 2/Phase 3 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Lamprene
Clinical Trial Phase Trials
Recruiting 5
Active, not recruiting 3
Not yet recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Lamprene

Sponsor Name

Sponsor Name for Lamprene
Sponsor Trials
Wits Health Consortium (Pty) Ltd 5
London School of Hygiene and Tropical Medicine 4
Ministry of Health, Republic of Uzbekistan 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Lamprene
Sponsor Trials
Other 105
Industry 7
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
McKesson
McKinsey
Harvard Business School
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.